Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron.The surge, which nearly doubles the company’s market cap in a single session, signals that Wall Street sees a viable new contender in the lucrative weight-loss market.The development comes as a direct challenge to giants like Novo Nordisk and Eli Lilly, who continue to dominate the weight-loss market.Structure Therapeutics stock: Why this trial win matter?The obesity sector is currently defined by needles. But, Structure Therapeutics’ massive stock rally reflects the market’s voracious appetite for oral alternatives.With the global weight-loss market projected to exceed $100 billion by 2030, investors are hunting for “next-gen” players who can deliver efficacy in a pill.Structure’s Phase 2b success positions aleniglipron as a serious clinical asset rather than a speculative science project.Double-digit weight lossThe catalyst for the Structure Therapeutics stock was clear-cut efficacy data that met the market’s high bar.In the Phase 2b study, patients taking a 120 mg daily dose of aleniglipron achieved a placebo-adjusted mean weight reduction of 11.3% over 36 weeks.Perhaps more compelling for investors looking at the “best-case” scenario, a separate cohort in a different study showed weight loss climbing as high as 15.3% at higher doses.Perhaps more compelling for investors looking at the “best-case” scenario, a separate cohort in a different study showed weight loss climbing as high as 15.3% at higher doses.The market reaction was immediate as Structure Therapeutics stock opened significantly higher and sustained buying pressure throughout the morning, pushing year-to-date gains to roughly 95%.Beyond the raw numbers, the company confirmed that the drug’s safety profile remains clean enough to proceed, announcing plans to initiate a Phase 3 program by the middle of 2026.What analysts are sayingWall Street’s response has been swift, with analysts scrambling to update their models. The consensus view is that aleniglipron has passed a critical test of competitiveness.Analysts are closely scrutinizing the durability of the weight loss and the side-effect profile compared to existing GLP-1 agonists.While safety data was generally positive, the path to regulatory approval will require a spotless Phase 3 execution.The main question moving forward is whether Structure can replicate these results in a larger, more diverse patient population next year.Moreover, the analysts will also take a closer look at its speed as it must be fast enough to capture market share before the window closes.While Structure Therapeutics enjoyed its breakout moment, the news sent a ripple of unease through the broader sector.Competitors saw mixed trading, with heavyweights like Eli Lilly and Novo Nordisk slipping modestly as traders rotated capital into the high-growth challenger.The post Structure Therapeutics stock: what’s driving sudden 103% jump in GPCR shares? appeared first on InvezzStructure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron.The surge, which nearly doubles the company’s market cap in a single session, signals that Wall Street sees a viable new contender in the lucrative weight-loss market.The development comes as a direct challenge to giants like Novo Nordisk and Eli Lilly, who continue to dominate the weight-loss market.Structure Therapeutics stock: Why this trial win matter?The obesity sector is currently defined by needles. But, Structure Therapeutics’ massive stock rally reflects the market’s voracious appetite for oral alternatives.With the global weight-loss market projected to exceed $100 billion by 2030, investors are hunting for “next-gen” players who can deliver efficacy in a pill.Structure’s Phase 2b success positions aleniglipron as a serious clinical asset rather than a speculative science project.Double-digit weight lossThe catalyst for the Structure Therapeutics stock was clear-cut efficacy data that met the market’s high bar.In the Phase 2b study, patients taking a 120 mg daily dose of aleniglipron achieved a placebo-adjusted mean weight reduction of 11.3% over 36 weeks.Perhaps more compelling for investors looking at the “best-case” scenario, a separate cohort in a different study showed weight loss climbing as high as 15.3% at higher doses.Perhaps more compelling for investors looking at the “best-case” scenario, a separate cohort in a different study showed weight loss climbing as high as 15.3% at higher doses.The market reaction was immediate as Structure Therapeutics stock opened significantly higher and sustained buying pressure throughout the morning, pushing year-to-date gains to roughly 95%.Beyond the raw numbers, the company confirmed that the drug’s safety profile remains clean enough to proceed, announcing plans to initiate a Phase 3 program by the middle of 2026.What analysts are sayingWall Street’s response has been swift, with analysts scrambling to update their models. The consensus view is that aleniglipron has passed a critical test of competitiveness.Analysts are closely scrutinizing the durability of the weight loss and the side-effect profile compared to existing GLP-1 agonists.While safety data was generally positive, the path to regulatory approval will require a spotless Phase 3 execution.The main question moving forward is whether Structure can replicate these results in a larger, more diverse patient population next year.Moreover, the analysts will also take a closer look at its speed as it must be fast enough to capture market share before the window closes.While Structure Therapeutics enjoyed its breakout moment, the news sent a ripple of unease through the broader sector.Competitors saw mixed trading, with heavyweights like Eli Lilly and Novo Nordisk slipping modestly as traders rotated capital into the high-growth challenger.The post Structure Therapeutics stock: what’s driving sudden 103% jump in GPCR shares? appeared first on Invezz